Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navigating the Difficulties of Nutrition During Cancer Care as a Nurse

April 26, 2025
By Claudia Aguilar Clancy, RN, FNP-C
News
Video
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.

Claudia Aguilar Clancy, RN, FNP-C, stated that addressing the nutritional needs of patients with various types of cancer can be difficult because it depends on several things, such as where the tumor developed and whether the patient requires a feeding tube.

During a conversation with CancerNetwork® at the 2025 Oncology Nursing Society Congress, Clancy, a nurse practitioner at Texas Oncology, discussed the complexities of helping patients meet their dietary and nutritional needs during cancer care. For those who have to use a feeding tube, soft foods and pureed foods are commonly used; Clancy stated that there is a long list of high-protein and soft food options that she shows her patients so they receive “the best fuel possible.”

Additionally, the type of treatment that a patient receives factors into what they can and cannot eat. If a patient receives radiation therapy directed at the gastrointestinal tract, Clancy will not serve that patient foods with high amounts of fiber because it may lead to more diarrhea or nausea.

The goal is not only to supply food that mitigates adverse effects (AEs) but also to provide a patient with the strength to get through their treatments.


Transcript:

I love my head and neck population. They are challenging, and they’re unique because it depends on where the tumor starts and it depends on where the feeding tube is going to go. Is it going to be in the stomach? Is it going to be in the jejunum, [also known as] the J-tube? If they can eat some [food], normally we assess, “OK, do they have a feeding tube? Can they eat orally?” If they cannot, then that’s when the formulas are obtained and [they get] soft foods and pureed foods. I give them a big list of all those [items] that are high protein but soft. They’re getting the best fuel possible.

Then we have our patients who don’t have a feeding tube, and those patients can eat. During radiation, depending on where the radiation is, if it’s a [gastrointestinal] tract radiation location, then we have to think about lower-fiber [foods] even though fiber is good, but at that particular time, it can cause more diarrhea and more of those [AEs] that we don’t want them to have. It could also cause a little more nausea and things like that.

We have to see what the diagnosis is to tailor the nutrition part of it so that they can be successful and have low [AEs] because of food but also have food that is going to help them get through the radiation. Food is powerful, and they need fuel. It’s a challenge because at that time, they don’t want to eat, but they have to eat.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Related Content

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 9th 2025
Podcast

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
September 9th 2025
Podcast

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article

The trial’s primary end points were EFS and OS. Secondary end points included mPR rate, pCR rate, AEs, and quality of life.

Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups

Russ Conroy
September 9th 2025
Article
Related Content

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 9th 2025
Podcast

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
September 9th 2025
Podcast

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article

The trial’s primary end points were EFS and OS. Secondary end points included mPR rate, pCR rate, AEs, and quality of life.

Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups

Russ Conroy
September 9th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.